|
|
|
| Expression and Significance of IP-10, IL-17 and miR-125a in Peripheral Blood PBMC of Patient with Ankylosing Spondylitis |
| DONG Zhen-yu, ZHOU Yu-bo, HUANG Yi-fei |
| Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region 830000 |
|
|
|
|
Abstract 【Objective】To investigate the levels and significance of inducible protein 10 (IP-10), interleukin-17 (IL-17) and miR-125a in peripheral blood mononuclear cells (PBMC) of patients with ankylosing spondylitis (AS). 【Methods】A total of 110 AS patients were selected as the observation group, and 100 healthy volunteers were selected as the control group. The expression of IP-10, IL-17 mRNA and miR-125a in PBMC were detected and compared between the two groups. 【Results】The relative expression levels of IP-10 and IL-17 mRNA in PBMC of the observation group were significantly higher than those of the control group (P<0.05), While there were no significant difference in the relative expression of miR-125a in two group (P>0.05). The relative expression levels of IP-10 and IL-17 mRNA in PBMC of patients in active phase were significantly higher than those in stable phase (P<0.05), however, there was no significant difference in the relative expression level of miR-125a between patients in active phase and stable phase (P>0.05). There were no significant difference in the expression levels of IP-10, IL-17 mRNA and miR-125a in PBMC between patients of different gender and age in the observation group (P>0.05). Levels of IP-10 and IL-17 mRNA were positively correlated with AS disease activity (ASDAS) score (r=0.343, 0.311, P<0.05), while there was no significant correlation of miR-125a with ASDAS score (r=0.112, P>0.05). 【Conclusion】The expression of IP-10 and IL-17 in PBMC of AS patients are significantly increased, which are related to the severity of the disease, while there is no significant abnormality in the expression of miR-125a.
|
|
Received: 07 May 2019
|
|
|
|
|
|
[1] Rumman A, Malki FA, Ghamdi SA, et al. Su1897-aggressive inflammatory bowel disease phenotype in patients with ankylosing spondylitis: a single-center experience[J].Gastroenterology,2018, 154(6): 624-628.
[2] Aherne ST, O'Neill F, Madden SF,et al. Abstract 1091: miR-125 family of miRNAs mediates prostate cancer cell proliferation and migration[J].Cancer Res,2016, 76(14 ):1091.
[3] Perezsanchez C, Fontugalde P, Ruizlimon P, et al. Circulating microRNAs as potential biomarkers of disease activity and structural damage in ankylosing spondylitis patients[J].Hum Mol Genet,2018, 27(5):875-890.
[4] 黄金星, 唐光辉, 文波, 等. 强直性脊柱炎患者PBMC中IP-10,IFN-γ和IL-4 mRNA表达水平及意义[J].中南医学科学杂志, 2019, 47(4):346-349.
[5] Erdes S, Nasonov E, Kunder E, et al. Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults. Clin Exp Rheumatol[J]. 2020,38(1):27-34.
[6] 杨彪,王瑶,赵晓光,等.γ干扰素诱导蛋白-10在强直性脊柱炎患者血清中的表达及其临床意义[J].山西医科大学学报, 2016, 47(5):459-462.
[7] 姜丽丽, 刘娟, 周浩彤,等. 基质金属蛋白酶7和干扰素-诱导蛋白10在类风湿关节炎合并肺间质病变中的意义[J].中华风湿病学杂志, 2018, 22(4):257-260.
[8] 任明亮, 刘鹄, 王潇娉,等. 强直性脊柱炎骨髓间充质干细胞诱导Th17/Treg失衡[J].脊柱外科杂志, 2016, 14(5):281-285.
[9] 解娟,归巧娣,刘文康,等. 血清IL-12、IL-17在强直性脊柱炎中的表达特征及相关性研究[J].临床和实验医学杂志, 2018,271(15):1621-1623.
[10] Carlos PS, Pilar FU, Patricia RL, et al. Circulating microRNAs as potential biomarkers of disease activity and structural damage in ankylosing spondylitis patients[J].Hum Mol Genet,2018,27(5):875-890. |
|
|
|
2021, Vol. 38 
